Therini Bio Raises Additional $39M Series A Financing to Advance Clinical Development of Neurodegenerative Disease Pipeline

Therini Bio完成额外3900万美元A轮融资，以推进神经退行性疾病管线的临床开发

- Angelini Ventures and Apollo Health Ventures join existing top-tier investor syndicate

- Angelini Ventures和Apollo Health Ventures加入现有的顶级投资者财团

- Follows original $36M Series A raise and brings Series A total to $75M

- 在原先3600万美元的A轮融资之后，此次融资使得A轮总金额达到7500万美元。

- Proceeds are being used to fund Phase 1b Alzheimer’s and DME studies, and bispecific development

- 收益正被用于资助第一阶段b部分的阿尔茨海默病和DME研究，以及双特异性开发

SACRAMENTO, Calif., May 14, 2025-- Therini Bio, Inc., a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction today announced that it raised $39 million in a Series A extension financing. The extension financing included new investors, Angelini Ventures and Apollo Health Ventures, in addition to existing investors SV Health Investors’ Biotech Fund and Dementia Discovery Fund, MRL Ventures Fund, Sanofi Ventures, Eli Lilly and Company, Dolby Family Ventures and Foundation for a Better World.

加利福尼亚州萨克拉门托，2025年5月14日——Therini Bio, Inc.是一家临床阶段的生物技术公司，致力于开发针对由血管功能障碍引发的神经退行性疾病的纤维蛋白靶向免疫疗法。该公司今天宣布，在A轮融资扩展中筹集了3900万美元。此次扩展融资包括新投资者Angelini Ventures和Apollo Health Ventures，以及现有投资者SV Health Investors的生物技术基金、痴呆症发现基金、MRL Ventures Fund、赛诺菲风险投资、礼来公司、Dolby Family Ventures和Foundation for a Better World。

This financing increased Therini Bio’s Series A total to $75M..

这笔融资使Therini Bio的A轮融资总额增至7500万美元。

Therini Bio anticipates using the proceeds to fund Phase 1b trials evaluating its lead candidate, THN391, for the treatment of Alzheimer’s Disease (AD) and Diabetic Macular Edema (DME), as well as support development of a fibrin/VEGF bispecific.

Therini Bio计划利用这笔资金资助评估其主要候选药物THN391的1b期临床试验，用于治疗阿尔茨海默病（AD）和糖尿病性黄斑水肿（DME），并支持开发一种纤维蛋白/VEGF双特异性抗体。

Therini Bio seeks to target the underlying causes of neurodegeneration. Factors such as aging, genetics and prevalent diseases, such as hypertension and diabetes, lead to vascular dysfunction and the accumulation of toxic fibrin deposits outside of blood vessels. These deposits induce chronic neuroinflammation, resulting in neuronal damage and severe neurogenerative diseases.

Therini Bio 旨在针对神经退行性病变的根本原因。衰老、遗传因素以及高血压和糖尿病等常见疾病会导致血管功能障碍，并在血管外积累有毒的纤维蛋白沉积物。这些沉积物引发慢性神经炎症，导致神经元损伤和严重的神经退行性疾病。

Therini Bio has developed a novel approach aimed at treating these devastating diseases by specifically targeting the inflammatory epitope on fibrin to halt the destructive effects of neuroinflammation..

Therini Bio开发了一种新方法，旨在通过特异性靶向纤维蛋白上的炎症表位来治疗这些毁灭性疾病，从而阻止神经炎症的破坏性影响。

THN391, a potential first-in-class, high-affinity humanized monoclonal antibody designed to selectively block fibrin-mediated neuroinflammation without affecting coagulation pathways, demonstrated activity in preventing vascular and neuronal degeneration in preclinical studies of AD and retinal diseases.

THN391 是一种潜在的首创高亲和力人源化单克隆抗体，旨在选择性阻断纤维蛋白介导的神经炎症而不影响凝血途径，在阿尔茨海默病（AD）和视网膜疾病的临床前研究中显示出预防血管和神经元退化的活性。

In a recent Phase 1a trial, THN391 was well-tolerated in healthy volunteers, showed no adverse hematological effects or impact on coagulation and fibrinolysis, lacked an anti-drug antibody response and had dose-proportional pharmacokinetics with a half-life supporting monthly dosing. Supported by the current data and financing, the experienced team at Therini Bio is preparing to begin dosing patients in Phase 1b trials evaluating THN391 in AD and DME..

在最近的 1a 期临床试验中，THN391 在健康志愿者中显示出良好的耐受性，未出现不良血液学影响或对凝血和纤溶的影响，没有产生抗药物抗体反应，并且其药代动力学呈剂量依赖性，半衰期支持每月一次给药。基于当前数据和资金支持，Therini Bio 的经验丰富的团队正准备开始在评估 THN391 治疗 AD 和 DME 的 1b 期试验中对患者进行给药。

Tara Nickerson, Ph.D., Chief Executive Officer of Therini Bio and an industry veteran who also played an instrumental role previously in several prominent private and public biotech financings, including as Chief Business Officer of Maze Therapeutics and Prothena Biosciences, remarked, “We are deeply grateful to partner with such a distinguished investor group, both new and old.

Therini Bio的首席执行官、行业资深人士塔拉·尼克森博士曾在多家知名的私营和公共生物技术融资中发挥了重要作用，包括担任Maze Therapeutics和Prothena Biosciences的首席商务官，她表示：“我们非常感激能与这样一群杰出的新老投资者合作。

Their support enables us to significantly advance our shared vision of delivering patients a rational, innovative approach to potentially treat their debilitating conditions, including Alzheimer’s disease and Diabetic Macular Edema. We look forward to advancing the Phase 1b trials to demonstrate the potential benefit of this novel mechanism in patients.”.

他们的支持使我们能够显著推进共同的愿景，即为患者提供一种合理且创新的方法来潜在治疗其衰弱性疾病，包括阿尔茨海默病和糖尿病性黄斑水肿。我们期待推进1b期试验，以证明这种新机制在患者中的潜在益处。”

Thomas Thestrup, Senior Principal at Angelini Ventures, who led the investment on behalf of Angelini Ventures stated, ”We are proud to support Therini Bio’s mission to address the underlying vascular and inflammatory drivers of neurodegenerative disease through a truly novel approach. As an active CNS investor, we are excited about Therini’s first-in-class selective antibody therapy targeting fibrin-mediated inflammation, offering a groundbreaking path to transform the treatment of diseases such as Alzheimer’s and DME.”.

Angelini Ventures的高级负责人托马斯·斯特鲁普代表Angelini Ventures领导了这项投资，他表示：“我们很自豪能够支持Therini Bio通过一种真正新颖的方法来解决神经退行性疾病的血管和炎症驱动因素的使命。作为一家活跃的中枢神经系统（CNS）领域投资者，我们对Therini首创的选择性抗体疗法感到兴奋，该疗法针对纤维蛋白介导的炎症，为改变阿尔茨海默病和糖尿病性黄斑水肿（DME）等疾病的治疗提供了突破性的途径。”

About

关于

Therini Bio is a clinical-stage biotech company developing immunotherapies for neuroinflammation in diseases driven by vascular dysfunction. Therini Bio is developing a pipeline of potential first-in-class therapies selectively targeting toxic fibrin accumulation for diseases, including Alzheimer’s disease and Diabetic Macular Edema, where destructive neuroinflammation plays a central role in the disease process.

Therini Bio是一家临床阶段的生物技术公司，致力于开发针对血管功能障碍相关疾病中神经炎症的免疫疗法。Therini Bio正在开发一系列潜在的首创疗法，选择性靶向有毒纤维蛋白积累，用于包括阿尔茨海默病和糖尿病性黄斑水肿等疾病，其中破坏性的神经炎症在疾病进程中起着核心作用。

Therini Bio’s top-tier syndicate of life sciences investors includes the Alzheimer’s Drug Discovery Foundation, Angelini Ventures, Apollo Health Ventures, SV Health Investors’ Biotech Fund and Dementia Discovery Fund, Dolby Family Ventures, Dreavent Biotech Investments, Eli Lilly and Company, Foundation for a Better World, MRL Ventures Fund, the therapeutics-focused corporate venture fund of Merck & Co., Inc., and Sanofi Ventures.

Therini Bio的一流生命科学投资者联盟包括阿尔茨海默病药物发现基金会、Angelini Ventures、Apollo Health Ventures、SV Health Investors的生物技术基金和痴呆症发现基金、Dolby Family Ventures、Dreavent Biotech Investments、礼来公司、美好世界基金会、MRL Ventures Fund（默克公司专注于治疗学的企业风险基金）以及赛诺菲风险投资。

For more information, visit www.therinibio.com..

欲了解更多信息，请访问 www.therinibio.com。

Contact:

联系人：

Tara Nickerson, Ph.D.

塔拉·尼克森，哲学博士

Chief Executive Officer

首席执行官

tnickerson@therinibio.com

tnickerson@therinibio.com